Overview

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Standard "3+3" dose escalation design of TKI258/XELOX in advanced gastric/gastro-oesophageal and colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborator:
Novartis
Treatments:
Capecitabine
Oxaliplatin